Welcome to our dedicated page for Edgewise Therapeutics SEC filings (Ticker: EWTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Edgewise Therapeutics, Inc. filings document a late-stage clinical biopharmaceutical company developing treatments for severe muscle diseases, including programs for muscular dystrophies and serious cardiac conditions. Form 8-K reports furnish quarterly and annual financial results, Regulation FD clinical-program disclosures, and material governance events.
The company’s proxy materials describe board structure, director elections, executive compensation, equity-award information, stockholder voting matters, and governance practices. Other disclosed matters include officer appointments, director appointments, compensatory arrangements, exhibits to earnings releases, and operating context for a development-stage drug pipeline.
Edgewise Therapeutics, Inc. director Edris Badreddin reported option exercises and related share sales. On January 21, 2026, he exercised multiple stock options for Edgewise common stock at exercise prices ranging from $0.39 to $1.93 per share, converting them into common shares held directly.
The same day, he sold shares of Edgewise common stock in several transactions marked with code "S". These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 24, 2025, at an average sale price of $29.44 per share, with individual trades occurring between $29.00 and $29.77. Following the reported transactions, Badreddin directly owned 19,820 shares of Edgewise common stock.
Eliem Therapeutics (symbol EWTX) has a holder planning to sell common shares under Rule 144. The notice covers 115,471 shares of common stock to be sold through J.P. Morgan Securities LLC on the Nasdaq market, with an approximate sale date of 01/21/2026. The aggregate market value of the planned sale is listed as 3,353,279, compared with 105,868,434 common shares outstanding.
The shares to be sold were acquired on 01/21/2026 through a stock option exercise from the issuer, paid for in cash on the same date. The person signing the notice represents that they are not aware of any material adverse, nonpublic information about the issuer’s current or future operations.
Robert Michael Carruthers filed a Rule 144 notice to sell 183,867 shares of common stock of EWTX through Morgan Stanley Smith Barney on the NASDAQ, with an aggregate market value of $5,168,722.01. These shares were acquired on 01/20/2026 by exercising options under a registered plan with the issuer, paid in cash on the same date. The filing reports that 105,868,434 shares of this class were outstanding. It also lists prior sales over the past three months, including 116,665 shares on 12/29/2025 for $3,039,811.57, 70,000 shares on 11/17/2025 for $1,566,586.00, and 180,872 shares on 01/15/2026 for $4,804,322.06. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer.
EWTX shareholder Robert Michael Carruthers has filed to sell 180,872 common shares through Morgan Stanley Smith Barney LLC on or about 01/15/2026 under Rule 144. The filing lists an aggregate market value of $4,804,322.06 for these shares, with 105,868,434 common shares of the issuer reported as outstanding.
The shares to be sold were acquired on 01/15/2026 by exercising options under a registered plan in two transactions of 166,665 and 14,207 shares, both paid in cash. Over the prior three months, Carruthers sold additional common shares in two transactions: 116,665 shares on 12/29/2025 for gross proceeds of $3,039,811.57 and 70,000 shares on 11/17/2025 for $1,566,586.00.
Edgewise Therapeutics, Inc. (EWTX) reported a routine equity compensation grant to a director on a Form 4. On November 19, 2025, the reporting person received stock options to purchase 45,150 shares of common stock at an exercise price of $22.34 per share. These options begin vesting on December 19, 2025, with 1/36th of the shares vesting each month, so full vesting occurs over three years as long as the director continues as a service provider through each vesting date. The options have an expiration date of November 19, 2035, meaning they can be exercised anytime after vesting and before that date, subject to the applicable plan and agreement terms.
Edgewise Therapeutics, Inc. (EWTX) director files Form 3 reporting no holdings. The filing states that director Christopher Nathan Martin, through his attorney-in-fact, filed an initial statement of beneficial ownership and reported that he does not beneficially own any Edgewise Therapeutics securities as of the event date.
Edgewise Therapeutics, Inc. (EWTX) reported that its Board of Directors appointed Christopher Martin as a Class I director, with his term running through the company’s 2028 annual meeting of stockholders. Martin, age 49, brings extensive commercial experience from roles at Verona Pharma, SK Life Science, Cempra, and Salix Pharmaceuticals, including leading launch strategies for several first‑in‑class products.
Martin was deemed independent under SEC and Nasdaq rules and has no related‑party transactions requiring disclosure. He will receive an annual cash retainer of $40,000 for board service and a stock option grant with a grant date fair value of approximately $700,000, vesting in equal monthly installments over 36 months, with full vesting upon a Change in Control as defined in the company’s 2021 Equity Incentive Plan.
Edgewise Therapeutics (EWTX) filed a Form 4 showing insider activity. On 11/12/2025, a Director and Chief Scientific Officer exercised stock options and sold shares the same day. The insider exercised 100,000 options at an exercise price of $0.18 (code M) and sold 100,000 shares of common stock at an average price of $21.1245 (code S), with trades executed between $21.00 and $21.35.
Following these transactions, the insider directly beneficially owned 23,400 common shares. In addition, 1,147,365 derivative securities (stock options) remained beneficially owned. The exercised option referenced had become exercisable on 06/27/2021 and carries an expiration date of 06/27/2032.
Edgewise Therapeutics, Inc. director reports open-market share purchase. A reporting person who serves as a director of Edgewise Therapeutics, Inc. (EWTX) bought 10,700 shares of common stock on 11/11/2025 in an open-market transaction coded as a purchase. The shares were acquired at an average price of $18.6358 per share, with multiple trades executed in a price range from $18.55 to $18.65. Following this transaction, the director beneficially owns 23,702 shares of Edgewise Therapeutics common stock, held directly. The reporting person has indicated a willingness to provide detailed trade-by-trade pricing information upon request.
Edgewise Therapeutics, Inc. (EWTX) reported new equity awards to its Chief Financial Officer, Michael Nofi. On 11/10/2025, he received 43,750 restricted stock units (RSUs) that convert into the same number of common shares, vesting in four equal annual installments beginning on November 10, 2026. He was also granted stock options to purchase 262,500 shares of common stock at an exercise price of $18.28 per share. One quarter of these options vest on November 10, 2026, and the remaining options vest in equal monthly installments over the following three years, contingent on his continued service.